The role of non-invasive scores in the diagnosis of hepatic fibrosis in people with type 2 diabetes

Authors

Keywords:

steatotic liver disease, non-invasive scores, liverfibrosis, type 2 diabetes

Abstract

Liver fibrosis represents one of the most pressing problems of steatotic liver disease, as it contributes to disease progression and increases the risk of mortality. Early detection of people with type 2 diabetes and liver fibrosis is essential in disease management, to avoid complications. The study is based on the review of the research articles published during the period 01.01.2007-30.05.2024, in the databases PubMed, ScienceDirect, and Google Academic. From the total number of 280 articles, 27 relevant articles were selected. Non-invasive scores are algorithms that incorporate different clinical variables and biomarkers, increasing the sensitivity and specificity of identifying liver fibrosis. The most commonly used scores are APRI, BARD, NFS, FibroTest, and FIB-4. Recent studies demonstrated that these scores have been validated and can be applied in clinical practice. However, the FIB-4 score exceeds the accuracy of other non-invasive scores and has been recommended by several international societies as a screening method for liver fibrosis in people with type 2 diabetes. Noninvasive scores represent promising, useful, and cost-effective diagnostic methods for the diagnosis of liver fibrosis in people with type 2 diabetes. They provide an assessment of prognosis and the development of effective personalized management strategies, eliminating the risks associated with liver biopsy.

References

1. AJMERA V., CEPIN S., TESFAI K. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. In: J. Hepatol. 2023, vol. 78, nr. 3, pp. 471-478, https://doi.org/10.1016/j.jhep.2022.11.010

2. ALHINAI A., PATEL K., FONSECA V. et al. Non-invasive diagnosis of nonalcoholic fatty liver disease in pa-tients with type 2 diabetes. In: Journal of Diabetes and its Complications. 2021, vol. 35, nr. 9, pp. 1-12. https://doi.org/10.1016/j.jdiacomp.2021.107978

3. ALKAYYALI T., QUATRANJI L., KAYA E. et al. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mel-litus: a study in biopsy-proven non-alcoholic fatty liver disease. In: Acta Diabetol. 2020, vol. 57, nr. 5, pp. 613-618. https://doi.org/10.1007/s00592-019-01467-7

4. ANGULO P., HUI J., MARCHESINI G. et al. The NAFLD fi-brosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. In: Hepatology. 2007, vol. 45, nr. 4, pp. 846-854. https://doi.org/10.1002/hep.21496

5. BINET Q., LANTHIER N., LOUMAYE A. et al. Non-invasive screening, staging and management of metabolic dysfunctionassociated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients : what do we know so far ? In: Acta Gastroenterol. Belg. 2022, vol. 85, nr. 2, pp. 346-357.

https://doi.org/10.51821/85.2.9775

6. BRILL F., MCPHAUL M., CALFIELD M., et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. In: J Investig Med. 2019, vol. 67, pp. 303-311. https://doi.org/10.1136/jim-2018-000864

7. CAMPOS-MURGUIA A., RUIZ-MARGAIN A., GONZALEZ-REGUEIRO J. et al. Clinical assessment and man-agement of liver fibrosis in nonalcoholic fatty liver disease. In: World J. Gastroenterol. 2020, vol. 26, nr. 39, pp. 5919-5943. https://doi.org/10.3748/wjg.v26.i39.5919

8. CASTERA L., FRIEDRICH-RUST M., LOOMBA R. Nonin-vasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. In: Gastroenterology. 2019, vol. 156, nr. 5, pp. 1264-1281. https://doi.org/10.1053/j.gastro.2018.12.036

9. CIARDULLO S., MURACA E., PERRA S. et al. Screen-ing for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. In: BMJ Open Diabetes Res. Care. 2020, vol. 8, nr. 1, pp. 1-9. https://doi.org/10.1136/bmjdrc-2019-000904

10. ELSAYED A., ALEPPO N., ARODA V. et al. Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. In: Diabetes Care. 2023, vol 46, nr. 9, pp. 1718-1720. https://doi.org/10.2337/dc23-ad09

11. FRIEDRICH-RUST M., ROSENBERG W., PARKES J. et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. In: BMC Gas-troenterol. 2010, vol. 10, pp. 1-8. https://doi.org/10.1186/1471-230X-10-103

12. GRACEN L., HAYWARD K., IRVINE K. et al. Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosis. In: J. Hepatol. 2022, vol. 77, nr. 4, pp. 1219-1221. https://doi.org/10.1016/j.jhep.2022.06.016

13. HARISSON S., OLIVER D., ARNOLD H. et al. Develop-ment and validation of a simple NAFLD clinical scor-ing system for identifying patients without advanced disease. In: Gut. 2008, vol. 57, nr. 10, pp. 1441-1447. https://doi.org/10.1136/gut.2007.146019

14. JEEYAVUDEEN M., KHAN S., FOUDA S. et al. Manage-ment of metabolic-associated fatty liver disease: The diabetology perspective. In: World Journal of Gastroenterology. 2023, vol. 29, nr. 1, pp. 126-143. https://doi.org/10.3748/wjg.v29.i1.126

15. KIM R., DENG J., REASO J. et al. Noninvasive Fibrosis Screening in Fatty Liver Disease Among Vulnerable Populations: Impact of Diabetes and Obesity on FIB-4 Score Accuracy. In: Diabetes Care. 2022, vol. 45, nr. 10, pp. 2449-2451. https://doi.org/10.2337/dc22-0556

16. LEE J., VALI Y., BOURSIER J. et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. In: Liver Int. 2021, vol. 41, nr. 2, pp. 261-270, https://doi.org/10.1111/liv.14669

17. MANSOUR D., GRAPES A., HERCOVITZ M. et al. Embed-ding assessment of liver fibrosis into routine diabetic review in primary care. In: JHEP Reports. 2021, vol. 3, nr. 4, pp. 1-10. https://doi.org/10.1016/j.jhepr.2021.100293

18. MCPHERSON S., HARDY T., DUFOUR J. et al. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. In: Am. J. Gastroenterol. 2017, vol. 112, nr. 5, pp. 740-751. https://doi.org/10.1038/ajg.2016.453

19. PATEL P., HOSSAIN F., HORSFALL L. et al. A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. In: Hepatol. Commun. 2018, vol. 2, nr. 8, pp. 897-909, https://doi.org/10.1002/hep4.1208

20. RINELLA M., NEUSCHWANDER-TETRI B., SIDDIQUI M. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. In: Hepatology. 2023, vol. 77, nr. 5, pp. 1797-1835. https://doi.org/10.1097/HEP.0000000000000323

21. SHAJI N., SINHAI A., JOSHI R. Assessment of liver fibro-sis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome. In: J. Assoc. Physicians India. 2020, vol. 70, nr. 4, pp. 11-12. https://doi.org/10.7759/cureus.22682

22. STAUFER K, HALILBASIC E., SPINDELBOECK W. et al. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. In: United Eur. Gastroenterol. J. 2019, vol. 7, nr. 8, pp. 1113-1123, https://doi.org/10.1177/2050640619865133

23. TREEPRASERTSUK S., BJORNSSON E., ENDERS F. et al. NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients. In: World J. Gastroenterol. 2013, vol. 19, nr. 8, pp. 1219-1229. https://doi.org/10.3748/wjg.v19.i8.1219

24. UNSAL İ., CALAPKULU M. Calapkulu, SENKAR M. Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease. In: Sci. Reports. 2022, vol. 12, nr. 1, pp. 1-8, https://doi.org/10.1038/s41598-021-04361-x

25. VIEIRA BARBOSA J., LAI M. Nonalcoholic Fatty Liver Dis-ease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. In: Hepatol. Commun. 2021, vol. 5, nr. 2, pp. 158-167. https://doi.org/10.1002/hep4.1618

26. WATTACHERIL J., ABDELMALEK M., LIM J. et al. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review. In: Gastroenterology. 2023, vol. 165, nr. 4, pp. 1080-1088. https://doi.org/10.1053/j.gastro.2023.06.013

27. YOUNOSSI Z., COREY K., ALKHOURI N. et al. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. In: Aliment. Pharmacol. Ther. 2020, vol. 52, nr. 3, pp. 513-526. https://doi.org/10.1111/apt.15830

Downloads

Published

2026-04-14

Issue

No. 5(102) (2024)

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

[1]
Darii, F. et al. 2026. The role of non-invasive scores in the diagnosis of hepatic fibrosis in people with type 2 diabetes. Public Health, Economy and Management in Medicine. 5(102) (Apr. 2026), 71–75.

Most read articles by the same author(s)

Similar Articles

1-10 of 313

You may also start an advanced similarity search for this article.